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The burden of viral respiratory infections in young children 
in low-resource settings
Acute lower respiratory infections (ALRI), encompassing 
bacterial and viral pneumonias, acute viral bronchiolitis, 
and bacterial and viral bronchitis, remain the leading 
cause of global child mortality.1 The thrust of global 
prevention and treatment efforts has been directed 
against bacterial causes of ALRI, and deaths from 
bacterial pneumonia have decreased substantially 
since 1990 because of improved access to health care 
and life-saving antibiotics, as well as increased use of 
vaccines targeted at bacterial respiratory pathogens. 
The leading causes of ALRI now are viral infections, with 
respiratory syncytial virus, influenza virus, parainfluenza 
virus, rhinovirus, and human metapneumovirus among 
the top viral causes of ALRI in children, particularly in 
low-resource settings.2 Prevention and treatment of 
viral pathogens could therefore substantially affect 
childhood ALRI outcomes.
In The Lancet Global Health, Xin Wang and colleagues3 
estimated the regional and global burden of influenza-
virus-associated ALRI in children younger than 5 years 
in 2018. Compared with their previous estimates4 in 
2008 (35 per 1000 children per year [95% CI 22–55]), 
the authors estimated a lower incidence of influenza-
virus-associated ALRI in 2018 (15·6 per 1000 children 
per year [uncertainty range 10·3–23·6]) for ages 
0–4 years in developing countries. The estimated 
proportion of childhood influenza virus ALRI episodes 
has also decreased from 13% in 2008 to 7% in 2018. 
Influenza virus accounted for 5% of ALRI hospital 
admissions and 4% of ALRI deaths in children under 
5 years. However, about 23% of the hospital admissions 
and 36% of the in-hospital deaths were in infants 
under 6 months. With 81% of the in-hospital deaths 
occurring in low-resource countries, the data show that 
much needs to be done to tackle the huge burden of 
influenza-associated morbidity and mortality in these 
settings.
Nevertheless, there are few representative data 
from south Asia and sub-Saharan Africa, regions with 
a disproportionally higher burden of global under-5 
mortality, and the investigators rightly indicate the 
need for high-quality, in-hospital, mortality data from 
low-income countries to improve estimates of global 
in-hospital mortality. The inclusion of only laboratory-
confirmed influenza infection morbidity and mortality 
data is a strength of the evidence base for the estimates 
in this study but would invariably have precluded 
studies from low-to-middle-income countries where 
there are few adequate diagnostic tools. Such data are 
essential to clarify the disease burden and subsequently 
inform evidence-based vaccination strategies. The wide 
confidence intervals around the estimates in Wang and 
colleagues’3 comprehensive systematic review highlight 
the diagnostic issues.
Although the overall decline in influenza virus ALRI 
reported by Wang and colleagues is good news,3 the 
absolute numbers of children affected by influenza 
virus ALRI with potentially serious consequences 
are staggering, and it is concerning that a fifth of 
influenza virus ALRI hospital admissions and a third 
of in-hospital deaths occurred in infants younger than 
6 months. Gaps in the availability of supportive care 
options and antiviral drugs (where indicated) for viral 
pneumonias in low-resource settings are likely to 
have contributed to the subsequent poor outcomes.5 
Despite the reduction in pneumonia-related childhood 
deaths in children under 5 years, there have been 
fewer reductions in pneumonia-related and sepsis-
related mortality among neonates.6,7 The ANISA study 
of the aetiology of early infant deaths also identified 
viral infections, notably respiratory syncytial virus, 
as the leading cause of serious infections among 
neonates and young infants in south Asia.8 With no 
respiratory viral vaccines licensed for use in this age 
group, very young children will remain vulnerable. 
Some of the gaps in protection could be bridged by 
vaccinating mothers during pregnancy.9 Improvements 
in delivery of oxygen to newborn babies and young 
children affected by pneumonia are also required.10 In 
the meantime, we ought to ensure that the licensed 
influenza vaccines can reach as many target groups as 
possible.
BK reports grants from UKRI and other international funders for her vaccine 
research, and travel support from vaccine companies for attendance at advisory 
board meetings. OTI became an employee of Sanofi Pasteur on Jan 20, 2020, 
after having completed the writing of this Comment. UO declares no competing 
interests.
Published Online 
February 20, 2020 
https://doi.org/10.1016/
S2214-109X(20)30037-1
See Articles page e497
Comment
e455 www.thelancet.com/lancetgh   Vol 8   April 2020
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open 
Access article under the CC BY 4.0 license.
*Uduak Okomo, Olubukola T Idoko, Beate Kampmann
uokomo@mrc.gm
Vaccines & Immunity Theme, Medical Research Council Unit, The Gambia at 
London School of Hygiene and Tropical Medicine, Fajara, PO Box 273, 
The Gambia (UO, OTI, BK); Vaccine Centre, Faculty of Infectious and Tropical 
Diseases, London School of Hygiene and Tropical Medicine, London, UK (BK)
1 UN Inter-agency Group for Child Mortality Estimation. Levels & trends in 
child mortality: report 2019, estimates developed by the UN Inter-agency 
Group for Child Mortality Estimation, 2019. https://www.unicef.org/
media/60561/file/UN-IGME-child-mortality-report-2019.pdf (accessed 
Jan 10, 2020). 
2 Pneumonia Etiology Research for Child Health Study Group. Causes of 
severe pneumonia requiring hospital admission in children without HIV 
infection from Africa and Asia: the PERCH multi-country case-control 
study. Lancet 2019; 394: 757–79.
3 Wang X, Li Y, O’Brien KL, et al. Global burden of respiratory infections 
associated with seasonal influenza in children under 5 years in 2018: 
a systematic review and modelling study. Lancet Glob Health 2020; 
published online Feb 20. https://doi.org/10.1016/S2214-109X(19)30545-5.
4 Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections 
due to seasonal influenza in young children: a systematic review and 
meta-analysis. Lancet 2011; 378: 1917–30.
5 Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D Jr, Thompson R. 
Respiratory syncytial virus: current and emerging treatment options. 
Clinicoecon Outcomes Res 6: 217–25.
6 Klugman KP, Rodgers GL. PERCH in perspective: what can it teach us 
about pneumonia etiology in children? Clin Infect Dis 2017; 
64 (suppl 3): S185–87.
7 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of 
under-5 mortality in 2000-15: an updated systematic analysis with 
implications for the Sustainable Development Goals. Lancet 2016; 
388: 3027–35.
8 Saha SK, Schrag SJ, El Arifeen S, et al. Causes and incidence of community-
acquired serious infections among young children in south Asia (ANISA): 
an observational cohort study. Lancet 2018; 392: 145–59.
9 Saso A, Kampmann B. Vaccination against respiratory syncytial virus in 
pregnancy: a suitable tool to combat global infant morbidity and 
mortality? Lancet Infect Dis 2016; 16: e153–63.
10 Duke T, Graham SM, Cherian MN, et al. Oxygen is an essential medicine: 
a call for international action. Int J Tuberc Lung Dis 2010; 14: 1362–68.
